RDIF. Health care

History

2020: Selection of health care as the priority investment direction

The Russian Direct Investment Fund (RDIF, a sovereign fund of the Russian Federation) announced on December 2, 2020 Zdrav.Expert selection of the direction "RDIF. Health care" as strategic investment priorities for the purpose of project implementation in the field of health care and also about formation of a specialized command responsible for this direction.

RDIF selected health care as the priority investment direction. Photo source: cluster.dasi27.ru

Development of investments in the field of health care is continuation of the activity of RDIF connected with fight against a koronavirusny infection and also the previous projects of Fund in the field of the medicine and health protection implemented within the investment strategy directed to improvement of quality of life.

In this regard the decision on appointment as the director of RDIF of development in the field of health care of Nina Kandelaki, the former CEO in Russia and the CIS by GE Healthcare, one of global manufacturers of the hi-tech medical equipment is made.

Nina Kandelaki will head a team of the new and acting staff of Fund who is professionals of world level in the field of the health care and investments, for the purpose of development existing and start of new projects on this strategic direction.

At the beginning of 2020 RDIF focused efforts on three key directions of fight against a koronavirusny infection: tests, medicines and vaccine. Thanks to network of the international partnership and the saved-up internal examination in the field of health care the fund managed to achieve results on all directions.

The fund started "from scratch" production rossiysko-the Japanese diagnostic systems of EMG providing result in 30 minutes with a pinpoint accuracy both in stationary and in the figurative portable mini-laboratories which do not have analogs. Thanks to production of a diagnostic system of EMG of the Russian Federation became one of world leaders in the number of the executed tests.

Together with Himrar Group, RDIF started industrial production of the medicine "Avifavir", one of two medicines in the world registered against a coronavirus. Deliveries of Avifavir for the beginning of December, 2020 are performed to 15 countries of the world.

Together with Research center of epidemiology and microbiology of N.F. Gamalei of RDIF develops industrial production of the vaccine "Sputnik of V", the first-ever registered vaccine against the koronavirusny infection created on well studied platform of adenoviral vectors of the person. According to efficiency evaluation which was performed among 18,794 volunteers for the 28th day after receiving the first injection (the 7th day after receiving the second injection), the efficiency "Sputnik of V" was 91.4%. For December, 2020 requests for acquisition over 1.2 billion doses of the vaccine "Sputnik of V" arrived from more than 50 countries.

These investments became possible thanks to the previous experience of implementation of such projects as development of network of clinics "Mother and child"; the organization of the first concession in the field of nuclear medicine on the example of network diagnostics and treatment oncological diseases; creation of additional capacities and reorganization pharmaceutical of the companies "Geropharm", "R-Pharm" and Alium; start of service of online consultations and medical maintenance "Doktis"; development of Russian robot- the surgeon AST company and hi-tech prostheses the company "Motility".

In a work progress over projects on counteraction of a koronavirusny infection we saw the huge need for additional investments into health sector for Russia and around the world. These investments will allow to win a final victory over a present pandemic in the near future and also it is better to be prepared for possible threats for health of mankind in the future. We are ready to partnership and investments in the field of telemedicine, production of medicines, treatment of oncological diseases, development and production of vaccines, education of doctors and health workers. For this purpose in RDIF the team of professionals of a world class with work experience in the companies market leaders is formed. Already the share of investments in the field of health care can soon exceed 15% of total portfolio of RDIF, and the number of clients of our portfolio companies working in this sector will make more than 20 million people, told Kirill Dmitriyev, the CEO of the Russian Direct Investment Fund (RDIF)